about
Prognostic importance of defibrillator shocks in patients with heart failureDebate: Do all patients with heart failure require implantable defibrillators to prevent sudden death?HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-UpNumber of P-wave fragmentations on P-SAECG correlates with infiltrated atrial fatOccurrence of implantable defibrillator events in patients with syncope and nonischemic dilated cardiomyopathy.Does the initial presentation of patients with implantable defibrillator influence the outcome?Accuracy of fluoroscopic localization of the Crista terminalis documented by intracardiac echocardiography.Frequent additional tachyarrhythmias in patients with inappropriate sinus tachycardia undergoing sinus node modification: an important cause of symptom recurrence.Interactions of antiarrhythmic drugs and implantable devices in controlling ventricular tachycardia and fibrillation.How to recognize, manage, and prevent complications during atrial fibrillation ablation.Electrocardiographic recognition and ablation of outflow tract ventricular tachycardia.Utility of intracardiac echocardiography in left heart ablation for tachyarrhythmias.Venice Chart international consensus document on atrial fibrillation ablation.Atrial fibrillation is common after ablation of isolated atrial flutter during long-term follow-up.Using the surface electrocardiogram to localize the origin of idiopathic ventricular tachycardia.Venice Chart international consensus document on atrial fibrillation ablation: 2011 update.Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.The substrate and ablation of ventricular tachycardia in patients with nonischemic cardiomyopathy.Randomized ablation strategies for the treatment of persistent atrial fibrillation: RASTA study.Outcomes of catheter ablation of ventricular tachycardia with mechanical hemodynamic support: An analysis of the Medicare database.The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation.Circadian variation of ventricular arrhythmia recurrences after cardioverter-defibrillator implantation in patients with healed myocardial infarcts.Ventricular tachycardia in patients without structural heart disease.Implantable defibrillator diagnostic storage capabilities: evolution, current status, and future utilization.Effect of high-current stimulation in patients with sustained ventricular tachycardia rendered noninducible by antiarrhythmic drugs.Adenosine as an antiarrhythmic agent.Flecainide and propafenone induced ST-segment elevation in patients with atrial fibrillation: clue to specificity of Brugada-type electrocardiographic changes.Safety of the open-irrigated ablation catheter for radiofrequency ablation: safety analysis from six clinical studies.Incidence and predictors of mortality following ablation of ventricular tachycardia in patients with an implantable cardioverter-defibrillator.Time to recurrence of atrial fibrillation influences outcome following catheter ablation.Nearly uniform failure of atrial flutter ablation and continuation of antiarrhythmic agents (hybrid therapy) for the long-term control of atrial fibrillation.Clinical predictors and outcomes associated with acute return of pulmonary vein conduction during pulmonary vein isolation for treatment of atrial fibrillation.Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study.Influence of gender on inducibility of ventricular arrhythmias in survivors of cardiac arrest with coronary artery disease.Irrigated radiofrequency catheter ablation guided by electroanatomic mapping for recurrent ventricular tachycardia after myocardial infarction: the multicenter thermocool ventricular tachycardia ablation trial.Efficacy and safety of targeted focal ablation versus PV isolation assisted by magnetic electroanatomic mapping.Surgical ablation of refractory ventricular tachycardia in patients with nonischemic cardiomyopathy.Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation.Implantable cardioverter defibrillator events in patients with asymptomatic nonsustained ventricular tachycardia: is device implantation justified?Effect of heart rate and isoproterenol on pulmonary vein flow velocity following radiofrequency ablation: a Doppler color flow imaging study.
P50
Q24631203-BE00A833-65CC-4532-8206-63408F6F4D2AQ24792670-0B4D746D-2E48-40BB-B7DC-84889D6B1FB3Q28305515-C4DBA229-D991-4E78-8825-89476D607B3BQ30775739-767A48A4-4BB6-40A5-ADB1-5C4C2FB1EF37Q33147113-893C9861-8607-41C2-AAE9-276D31DBE946Q33175147-76D4DA60-9A25-439F-BF03-13BC43FBABE4Q33998124-68D589D4-F797-4026-A08A-0FA843A10117Q34637174-BA11727F-5023-4EFC-81F4-25A73D555195Q34778166-98D82B48-AD33-464C-8DB5-C14B193C1B79Q36697454-2F74520B-C101-4304-AB8E-D70F7309EFE7Q36753062-04AFE257-09E2-4B42-A922-16F1E617C982Q36800499-BB02BE30-C1AC-4B01-8D34-7D034B14D628Q36800522-561505AF-1C92-4866-892F-9AD45B956014Q36901290-E2FF2AC0-1B23-4245-B48B-A44C61655B47Q38035009-C3F7F18E-7344-460A-90B7-B144C52008AFQ38041202-EC349DBD-2DCF-473E-83C1-01E90CE65534Q38079915-65F264CE-E25A-4529-A6EA-23E860ECA419Q38121724-727836AC-8906-43FA-86DD-AAB72D2115A5Q38480087-4AF40C15-E1CB-4060-9F20-CF217D543565Q38628892-564D0149-1ADF-4356-84B2-24C17EB698AAQ39899229-BD282A22-272A-4806-91BE-FE7FDF073685Q40532352-24114337-B973-4A73-9691-D5A2B88183B2Q40779041-906EE11C-1A65-413A-AC4B-091E6ECF1D2EQ40854707-E8594550-C9C7-4EA8-AE26-1E909D73DB00Q41110541-2A85A210-165F-4C7C-9416-DFDE8BB096C0Q41531534-DC29122C-2F7B-4849-998E-206C9099D941Q42168896-569FBF24-8890-4E4F-B0FA-ACC589BF8F79Q42659965-67D856EE-6184-4CF9-A408-BD51466EC15BQ43591921-F78DEEB9-3C19-4A5E-A9B4-EF93DB801F04Q43809077-D1F6570D-4FA0-4A71-BE41-1549924C57FEQ43827708-848B7327-3E67-43CA-9FDC-260E90DF3553Q44022073-8F8DCA8D-0282-4D5C-BF59-3309767C3FC7Q44272216-17CA5F53-15DF-4B91-9736-936F5891C01BQ44372258-B6BF068A-300B-4470-834C-CA49AE497843Q44406432-2460ECEE-4E8B-4B24-A4B0-840BEBDB06B3Q44437299-9FC4A7FD-E30E-466A-A64A-AE4170D6DDCBQ44640395-5975EA2C-1868-4C57-B32C-93CAFBE4EAAEQ44690504-CF3508D4-46A1-41F6-B4ED-211F9D7B2273Q44692922-303A3282-5B15-4E6A-AAD5-BDB52BE7CE59Q44888508-27B4FBE6-3D77-48DB-97B0-4CEAEB879B97
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francis E Marchlinski
@es
Francis E Marchlinski
@nl
Francis E Marchlinski
@sl
Francis E. Marchlinski
@en
type
label
Francis E Marchlinski
@es
Francis E Marchlinski
@nl
Francis E Marchlinski
@sl
Francis E. Marchlinski
@en
altLabel
F E Marchlinski
@en
prefLabel
Francis E Marchlinski
@es
Francis E Marchlinski
@nl
Francis E Marchlinski
@sl
Francis E. Marchlinski
@en
P106
P1153
7102234825
P21
P31
P4012
P496
0000-0001-7962-9423